Tumor Biology

, Volume 36, Issue 7, pp 5679–5685 | Cite as

Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer

  • Xiao-Hui Du
  • Hai-Liang Liu
  • Li Li
  • Shao-You Xia
  • Ning Ning
  • Zhen-Yu Zou
  • Da Teng
  • Chun-Hong Xiao
  • Rong Li
  • Ying-Xin Xu
Research Article


Surgery, chemotherapy, and radiotherapy have presented with the ability of killing tumor cells, as well as damaging the immune function, which can be corrected by the immunotherapy. The purpose of this perspective cohort study was to evaluate the efficacy of postoperative immunotherapies of tumor lysate-loaded dendritic cells (DC), in vitro DC-activated T (DC-AT), and activated T cells (ATC) combined with chemotherapy on the survival of patients with operable colorectal cancer. A total of 253 patients with primary colorectal cancer resection including 181patients receiving postoperative simple chemotherapy (control group) and 72 patients receiving immunotherapies of DC, DC-AT, and ATC combined with chemotherapy during the corresponding period (immunotherapy group) were enrolled in this perspective cohort study. The survival of these patients was analyzed. The immunotherapy group presented a higher 5-year overall survival rate than the control group (75.63 vs 67.81 %, P = 0.035), as well as 3-year overall survival rate (87.07 vs 74.80 %, P = 0.045). For patients with advanced cancer (TNM stages III and IV), immunotherapy significantly promotes mean survival than control subjects (59.74 ± 3.21 vs 49.99 ± 2.54 years, P = 0.034). Patients who received more than three cycles of immunotherapies had a higher 5-year overall survival rate than those with less than three cycles (82.10 vs 69.90 %, P = 0.035). No serious adverse effect was observed in the immunotherapy group. Postoperative immunotherapies with DC, DC-AT, and ATC combination can promote the survival of patients with operable colorectal cancer (Clinical Trials, ChiCTR-OCH-12002610).


Dendritic cells T cells Immunotherapy Survival Colorectal cancer 


Conflicts of interest



  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Fang YJ, Wu XJ, Zhao Q, Li LR, Lu ZH, Ding PR, et al. Hospital-based colorectal cancer survival trend of different tumor locations from 1960s to 2000s. PLoS ONE. 2013;8:e73528.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    DeVita Jr VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Cheever MA, Higano CS. Provenge (sipuleucel-t) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:3520–6.CrossRefGoogle Scholar
  5. 5.
    Zhao H, Fan Y, Li H, Yu J, Liu L, Cao S, Ren B, Yan F, Ren X. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm. 2013.Google Scholar
  6. 6.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother CII. 2007;56:2003–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Mann DL, Celluzzi CM, Hankey KG, Harris KM, Watanabe R, Hasumi K. Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers. Ann N Y Acad Sci. 2009;1174:41–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res. 2011;35:1136–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Thakur A, Schalk D, Sarkar SH, Al-Khadimi Z, Sarkar FH, Lum LG. A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother CII. 2012;61:497–509.CrossRefPubMedGoogle Scholar
  11. 11.
    Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358:2698–703.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011;239:27–44.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Rybojad P, Jablonka A, Wilczynska B, Tabarkiewicz J. Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer. Eur J Surg Oncol J Eur Soc Surg Oncol B Assoc Surg Oncol. 2013;39:1269–77.Google Scholar
  14. 14.
    Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer J Int Cancer. 2013.Google Scholar
  15. 15.
    Riedy M. Preventing colorectal cancer. Advance for NPs & PAs. 2013;4:18–21. quiz 22.Google Scholar
  16. 16.
    de la Cruz-Merino L, Henao Carrasco F, Vicente Baz D, Nogales Fernandez E, Reina Zoilo JJ, Pulido EG, et al. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol. 2011;2011:174149.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–96.PubMedGoogle Scholar
  18. 18.
    Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol. 1997;74:51–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Tang X, Liu T, Zang X, Liu H, Wang D, Chen H, et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS ONE. 2013;8:e62847.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med. 2012;10:48.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med. 2012;4:127ps128.CrossRefGoogle Scholar
  22. 22.
    Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199:815–24.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother CII. 2004;53:963–77.CrossRefPubMedGoogle Scholar
  24. 24.
    Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, et al. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. J Immunother. 2012;35:235–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012;109:4592–7.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, et al. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood. 2012;119:3073–83.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, Meneses-Flores M, Lopez-Gonzalez JS. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol. 2012;2012:741741.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood. 2011;117:1888–98.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xiao-Hui Du
    • 1
    • 3
  • Hai-Liang Liu
    • 1
  • Li Li
    • 1
  • Shao-You Xia
    • 3
  • Ning Ning
    • 3
  • Zhen-Yu Zou
    • 1
  • Da Teng
    • 1
  • Chun-Hong Xiao
    • 1
  • Rong Li
    • 2
  • Ying-Xin Xu
    • 1
  1. 1.General Surgery InstituteGeneral Hospital of PLABeijingChina
  2. 2.Department of General SurgeryGeneral Hospital of PLABeijingChina
  3. 3.Department of General SurgeryHainan Branch of the General Hospital of PLASanyaChina

Personalised recommendations